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Beta-Adrenergic Blocking Agents in the Treatment of Patients After 
a Myocardial Infarction 
Sidney Goldstein, MD' 
Beta-adrenergic blocking agents have been widely used in ischemic heart disease. They have 
achieved their greatest benefit in the secondary prevention of recurrent events in patients foltowing 
acute myocardial infarction (Ml). This is a review ofthe major clinical investigations exploring the 
effects of beta-adrenergic blocking agents in patients following acute Ml and in a variety of patient 
subsets. These data indicate that the routine use of beta-adrenergic blocking agenls in postinfarction 
patients resutts in a 25% to 35% decrease in mortality and has increased relative and absolute benef it 
in patients with ventricular ectopy and left ventricular dysfunction. The adverse effects trf beta-
adrenergic blocking agents are discussed which indicate that these drugs are welt tolerated wdh litde 
or no side effects. This review supports the obsen/ation that beta-adrenergic blocking agents have an 
important role in the treatment of patients following an acute Ml, with the exclusion of those with 
chronic lung disease and severe left ventricular dysfunction. (Henry Ford Hosp Med J 1991:39: 
200-5) 
B eta-adrenergic blocking agents represent the current thera-peutic foundation for the treatment of patients with acute 
and chronic coronary heart disease. Although this review deals 
with the use of these agents in the secondary prevention of 
postinfarction morbidity and mortality, their use in the treat-
ment of hypertension and chronic angina pectoris should also be 
emphasized. 
Clinical investigation of beta-blockers in ischemic heart dis-
ease began almost three decades ago with the initial observa-
tions by Ahlquist (1) who demonstrated the presence of (3-
adrenergic receptors in the cardiovascular system. The presence 
of p-adrenergic receptors led Black et al (2) to develop drugs 
that could block these receptors, thereby decreasing blood pres-
sure, pulse rate, and the metabolic requirements of the heart. A 
series of preliminary clinical studies almost two decades ago de-
scribed the benefit of p-adrenergic blocking agents in the treat-
ment of patients who have sustained acute myocardial infarction 
(Ml) (3-6). The results of these studies were confirmed by two 
m.ajor clinical trials of almost 7,000 patients, the Norwegian 
Multicenter Study (7) and the Beta-Blocker Heart Attack Trial 
(8) which examined the beta-blockers timolol and propranolol, 
respectively. Since these initial studies, reexamination of the 
original beta-blocker studies confirmed the inifial observafions 
of their benefit when administered to patients after an acute M I . 
Mechanism of Action of Beta-Blockers 
The initial studies by Black et al (2) demonstrated that beta-
blockers lower heart rate and blood pressure. These two physio-
logic effects result in the modification of myocardial oxygen de-
mands resulting in a salutary effect on the jeopardized ischemic 
myocardial tissue. It has been proposed that the degree to which 
pulse rate decreases as a result of beta-blocker therapy is a mea-
sure of its effect on improving survival (9) (Fig I ) . In addition to 
limiting infarct size, they modify the expression of ventricular 
ectopy both in the acute and chronic phases of M l . Whether this 
is a result of modifying myocardial ischemia or due to an inde-
pendent antiarrhythmic effect is not entirely clear. Animal stud-
ies demonstrate that beta-blockers exhibit a dose response effect 
on ventricular fibrillafion threshold when studied in both isch-
emic and nonischemic states (10). It is therefore clear that p-
adrenergic blocking agents have the potential of modifying two 
of the major risks facing patients with ischemic heart disease; 
the progression of myocardial ischemia and the development of 
life-threatening arrhythmias. In addition, Kaplan et al (11) dem-
onstrated that propranolol therapy was able to modulate diet-in-
duced coronary atherosclerosis in male cynomolgus monkeys 
by altering their behavioral response to stress. Cruickshank (12) 
reviewed the multiplicity of potential effects that these agents 
have on altering the progression of coronary artery disease. 
Beta-adrenergic blocking agents differ in their physiologic 
and pharmacologic effects. The major difference relates to the 
presence of P, selectivity. Metropolol, atenolol, and betaxalol, 
for instance, are considered drugs which have p, receptor block-
ing ability. These drugs tend to have a predominant, but not ex-
clusive, effect on chronotropic and inotropic blockade without 
affecting Pj receptors which cause peripheral vasoconstriction 
and bronchial constriction. The nonselective drugs such as pro-
pranolol, timolol, and nadolol do not have this selectivity and 
block both P, and P, receptors. It should be emphasized, how-
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ever, that this P, selecfivity is expressed at relatively low doses 
and is usually lost in the higher dose range. An additional unique 
characteristic of these agents is the intrinsic sympathomimetic 
or p-agonist effect. This can be expressed to a varying degree by 
a positive inotropic or chronotropic effect as seen with oxpren-
olol, pindolol, or acebutolol. All of these characteristics provide 
a spectrum of drugs available to the physician in the treatment of 
many forms of cardiovascular disease including hypertension, 
angina, and arrhythmias. The only drugs which have been tested 
on mortality in the chronic phase of acute Ml are propranolol 
(8), timolol (7), metoprolol (13), atenolol (14), sotalol (15), 
acebutolol (16), pindolol (17), and oxprenolol (18). All but pin-
dolol and oxprenolol have demonstrated a salutary effect on 
mortality. 
Effect of Beta-Blockers on Mortality 
and Morbidity 
A series of clinical trials examined the effect of different beta-
blockers on mortality (Table 1). The largest body of information 
has been reported by the Norwegian Multicenter Study Group 
(7) and the Beta-Blocker Heart Attack Trial (8). Timolol was ad-
ministered in doses of 10 mg twice daily and propranolol in 
doses of 60 to 80 mg three times a day. These two studies indi-
cate that when either timolol or propranolol was administered 
within two to three weeks postinfarction, a decrease in mortality 
between 25% and 36% in the first two years could be achieved, 
when compared to control patients receiving placebo (Figs 2 
and 3). In addition, in the timolol study a significant reduction in 
reinfarction and sudden death was observed in the active treat-
ment group. 
The relafive benefit of these drugs has been examined pro-
spectively and retrospectively in a number of different patient 
subsets and found to be consistentiy similar in almost all sub-
groups studied. The use of beta-blockers relative to infarct loca-
tion supports their efficacy, regardless of anterior or inferior in-
farction. Anterior infarcts, in general, have a placebo mortality 
rate twice that of inferior infarctions. The absolute benefit of 
these drugs relates to the inherent mortality risk of the particular 
subgroups. For example, patients who have experienced an an-
terior MI or who are older have a higher placebo mortality rate 
and therefore will achieve a greater total decrease in mortality as 
a result of beta-blocker therapy. The one exception are patients 
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Fig 1—Relationship between heart rate and reduction in mor-
tality induced by beta-blockers in survivors of acute MI. Note 
that beta-blockers with signiflcant intrinsic sympathomimetic 
activity (open circles) with little or no hradycardlc effect exert 
little effect on mortality. Beta-blockers without intrinsic sympa-
thomimetic activity (closed circles) with hradycardlc effect have 
the most significant effect on mortality. (From Kjekshus JK. Im-
portance of heart rate in determining beta-blocker efficacy in 
acute and long-term myocardial infarction intervention trials. 
Am J Cardiol I986;57;43F-49F. Reprinted with permission.) 
who experienced a non-Q wave MI who achieve a less apparent 
benefit. Subgroup analyses demonstrate no significant effect of 
propranolol or metoprolol in patients with a non-Q wave acute 
MI (19,20). In contrast, the timolol-treated patients with a non-
Q wave acute MI experienced a significant reduction in mortal-
ity (21). 
A number of different subgroups have been analyzed in order 
to ideniify those patients who can achieve the greatest benefit 
from beta-blocker therapy. In postinfarction pafients between 
65 to 75 years of age, fimolol exerted a similar decrease in rein-
farction and death (22), indicating its efficacy regardless of age. 
Jafri et al (23) examined the effect of propranolol on smokers 
(Fig 4) and observed that the greatest beneficial effect of pro-
Table 1 
Selected Results of Long-Term Beta-Blocker Trials for Secondary Prevention After Acute Myocardial Infarction 
Mean Mortality Reinfarction 
Numt)er of Entry From Follow-up Drug Placebo Drug Placebo 
Trial Patients Beta-Blocker M I (Days) (Months) (%) (%) (%) (%) 
Multicentre Intemational Study (1975) (6) 3,053 Practolol 1.0 24 6,3 8,2* 4 4 
Norwegian Multicenter Study (1981) (7) 1.884 Timolol 11.5 17 10,4 16.2* 10 14* 
Julian et al (1982) (15) 1,456 Sotalol 8.3 12 7,3 8.9 3 4 
Beta-Blocker Hean Attack Trial (1982) (8) 3,738 Propranolol 13,8 25 7.2 9.8* 4 5* 
Taylor et al (1982) (18) 1,103 Oxprenolol 14 months 48 9,5 10,2 1 1 12 
Boissel et al(1990)(16) 607 Acebutolol 2-22 10 5,7 11,0* 2 1,3 
•Statistically significanl difference. 
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pranolol on mortality was achieved in patients who smoked be-
fore their MI and those who continued to smoke after the event. 
Similar observations with timolol treatment were made by Ron-
nevik et al (24). 
The duration of therapy in these trials was limited to two to 
three years. The beneficial effects of therapy persisted through-
out that time. The Norwegian Multicenter Study on timolol was 
later extended to seven years, during which a continued benefi-
cial effect was observed (25). The effect of withdrawal of me-
toprolol in postinfarction patients was investigated after five 
to six years of therapy (26). Associated with metoprolol with-
drawal was an observed increase in symptoms and mortality in 
patients, when compared to patients who continued therapy. A 
recent study examined the risk of hospital death in patients tak-
ing a beta-blocker before a MI (27). That study indicated that 
prior beta-blocker therapy reduced the risk and severity of the 
subsequent acute infarction. Although ventricular fibrillafion 
was similar in patients regardless of prior beta-blocker therapy, 
patients taking a beta-blocker at the time of admission had a re-
duced extent of infarcfion and risk of death during the 28-day 
period after an acute MI. 
Fig 2—Life-table cumulative mortality curves for groups re-
ceiving piopranolol hydrochloride or placebo. N indicates total 
number of patients followed-up through each time point. (From 
the Beta-Blocker Heai-t Attack Trial Research Group. A ran-
domized trial of propranolol in patients with acute myocardial 
infarction. I. Mortality results. JAMA 1982;247:1707-14. Re-
printed with permission.) 
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Fig 3—Effect of timolol on mortality from all causes. (From the 
Norwegian Multicenter Study Group. Timolol-induced reduc-
tion in mortality and reinfarction in patients surviving acute 
myocardial infarction. N Engl J Med 1981 ;304:801-7. Re-
printed with permission.) 
Effect of Beta-Blockers on 
Ventricular Arrhythmias 
Ventricular ectopy, of course, has been a major predictor of 
both sudden death and long-term mortality in patients following 
MI. Observations in the Beta-Blocker Heart Attack Trial (28) 
demonstrated that the use of propranolol decreased the fre-
quency of ventricular ectopy in the first six weeks after the 
event. In patients with complex ventricular ectopy, propranolol 
therapy resulted in a greater decrease in mortality rate when 
compared to those patients without complex ventricular prema-
ture beats (29) (Fig 5). The effect of beta-blockers on mortality 
in patients with high-frequency ventricular ectopy is not solely 
related to ventricular ectopic beat suppression. It appears that 
they may also modify the biological milieu in which ventricular 
ectopy occurs, presumably rendering them less malignant. 
A number of studies examined the relafionship of beta-
blocker therapy on arrhythmias and hypokalemia and their ef-
fect on hypokalemia in patients receiving concomitant diuretic 
therapy. Patients taking a beta-blocking agent prior to their MI 
had higher serum potassium and less frequent ventricular ectopy 
on admission (30). This is presumedly due to the interference 
with NaK ATPase by Pj receptor blockade, preventing the intra-
cellular movement of K-F which occurs in the setting of in-
creased serum catecholamine associated with stress (31). 
Effect of Beta-Blockers in Patients with 
Decreased Left Ventricular Function 
Treatment with beta-blockers in postinfarction patients with 
left ventricular dysfunction has been of particular interest. Some 
concem was initially raised regarding the potential dangers of 
beta-blockers in patients with heart failure. Patients with severe 
left ventricular dysfunction manifested by shock and overt con-
gestive heart failure were excluded from most beta-blocker tri-
als. In the Beta-Blocker Heart Attack Trial, patients were in-
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Fig 4—Survival in smokers following MI was better in patients receiving propranolol in comparison to 
placebo. (From Jafri SM, Tilley BC, Peters R, Schultz LR, Goldstein S. Effects of cigarette smoking and 
propranolol in survivors of acute myocardial Infarction. Am J Cardiol 1990:65:271-6. Reprinted with per-
mission.) 
eluded who had congestive heart failure but whose heart failure 
was stabilized with digitalis and diuretic therapy. In those pa-
tients with a history of heart failure, propranolol therapy had the 
most profound beneficial effect on mortality (32) (Fig 6). Al-
though there was a slight increase in heart failure in the initial 
phases of the treatment of these patients, beta-blockers were 
well tolerated. In a similar study in patients with complex ar-
rhythmias and ventricular dysfunction, propranolol was also 
demonstrated to decrease sudden death significantly (33). A re-
cent analysis of the patients who received placebo in the Mul-
ticenter Diltiazem Postinfarction Trial (34) further confirmed 
these observations. Patients with evidence of heart failure and a 
left ventricular ejection fraction less than 30% and who received 
a beta-blocker had approximately a 50% decrease in mortality 
when compared to those who were not taking beta-blockers (Fig 
7). Although beta-blockers should be used cautiously in patients 
with left ventricular dysfunction, these patients have the greatest 
potential for benefit. 
Side Effects of Beta-Blocker Therapy 
Although it is suggested that beta-blockers are poorly toler-
ated due to a host of presumed adverse effects, blinded random-
ized placebo-controlled trials fail to support this presumption. 
The Beta-Blocker Heart Attack Trial extensively examined the 
0,69 
12%-
I Propranolol 
0 Placebo 
Risk 
0.84 Ratio 
Complex VPS Present Absent 
Total Mortality 
Present Absent 
Sudden Death 
Fig 5—Effect of propranolol on mortality and sudden death in 
relation to the presence of complex ventricular premature beats 
(VPBs), > 10/hr or i-uns or multiforms on 24-hour Holler moni-
tor at baseline. (Adaptedfrom Freidman LM, Byington RP, Ca-
pone RJ, Furherg CD, Goldstein S, Lichstein E,for the Beta-
Blocker Heart Attack Trial Research Group. Effect of propran-
olol in patients with myocardial infarction and ventricular 
arrhythmia. J Am Coll Cardiol 1986;7:1-8. Reproduced wfth 
permission.) 
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adverse effects of propranolol (8). Although patients with ob-
structive pulmonary disease were excluded from the study, there 
was a slight increase in bronchospasm and tiredness in patients 
taking propranolol (Table 2). Neuropsychiatric symptoms such 
as depression, nightmares, and insomnia did not occur any more 
frequently in patients receiving propranolol than in those receiv-
ing placebo. It is therefore clear that these drugs are well toler-
ated. Much of the perceived psychological reactions associated 
with beta-blocker therapy may in fact be related lo the increased 
occurrences of these symptoms in patients who experience a MI. 
I Propranolol 
0 Placebo 
CHF No CHF CHF No CHF CHF No CHF 
Total 
Mortality 
Cardiovascular 
Mortality 
Sudden 
Death 
Fig 6—The effect of propranolol on mortality in relation to a 
history of heart failure (CHF) at baseline in the Beta-Blocker 
Heart Attack Trial. (Adapted from Chadda K. Goldstein S, By-
ington R, Curb JD. Effect of propranolol after acute myocardial 
infarction in patients with congestive heart failure. Circulation 
1986;73:503-10. Reproduced whh permission.) 
I Beta blocker 
0 No beta blocker 
<30% 30%-39% 
Ejection Fraction 
>40% 
Fig 7—Risk of mortality was lower for patients receiving a beta-
blocker than for those not receiving a beta-blocker for each sub-
group of left ventricular ejection fraction. (Adapted from Lich-
stein E, Hager WD, Gregory JJ, Fleiss JE, Rolnitzky LM, Big-
ger JT, for the Multicenter Diltiazem Postinfarction Research 
Group. Relation between beta-adrenergic blocker use, various 
correlates of left ventricular function and the chance of develop-
ing congestive heart failure. J Am Coll Cardiol I990;16:I327-
32. Reproduced with permission.) 
One additional concem has been the effect of these dmgs on 
blood lipids. A recent analysis by Byington et al (35) of the 
Beta-Blocker Heart Attack Trial indicates that although there is 
a slight decrease in high-density lipoprotein cholesterol and an 
increase in triglycerides, there is no change in low-density lipo-
protein cholesterol. When mortality data were analyzed relative 
to these changes, propranolol continued to exert a profound ben-
eficial effect on mortality regardless of its effect on blood lipids. 
It appears, therefore, that these effects on serum lipids are of no 
importance either in the short- or long-term therapy of MI pa-
tients. 
These studies, as well as retrospective examinations of clini-
cal trials of beta-blockers, continue to develop data to support 
the benefits of the routine use of these dmgs in postinfarction 
patients. Their use appears to be indicated in all patients except 
those who have contraindications to their use. Beta-blockers ap-
pear to have their most significant absolute effect on high-risk 
patients including those with complex ventricular ectopy and 
left ventricular dysfunction. Therapy should be continued for 
the life of the patient, based on residual beneficial effects ob-
served at seven years following the acute event. 
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